Key Stats for Edward Lifesciences Stock
- This Week Performance: 4%
- 52-Week Range: $66 to $88
- Current Price: $79
What Happened to Edwards Lifesciences Stock?
Edwards Lifesciences (EW) gained 4% this week, pushing shares to $78.92 and back toward the upper half of their 52-week range, as investors responded to a stronger-than-expected Q4 earnings report released February 10.
Q4 revenue of $1.57 billion beat estimates by roughly $23 million, driven by TAVR sales growing 10.6% to $1.16 billion and TMTT sales exploding more than 40% to $156 million on surging adoption of PASCAL, EVOQUE, and the newly launched SAPIEN M3.
Management raised confidence in 2026 adjusted EPS guidance of $2.90 to $3.05, above the prior Street estimate of $2.89, and guided for 8% to 10% sales growth, citing multiple upcoming catalysts including next-gen PASCAL, U.S. tricuspid approval, and a potential CMS TAVR coverage expansion.
The market’s view of Edwards is shifting from a single-product TAVR story to a multi-therapy structural heart platform, with TMTT alone tracking toward $740 to $780 million in 2026 and a stated $2 billion revenue target by 2030.
Following the Q4 earnings call on February 10, where CEO Bernard Zovighian expressed increased confidence in the company’s 2026 outlook, 16 analysts rate the stock a Buy and 5 rate it Outperform against 12 Holds, with a mean price target of $96.50 implying roughly 22% upside from the current price of $78.92.
The EU dropping its antitrust investigation after Edwards scrapped its anti-copycat policy on February 16 removed a lingering overhang, clearing the path for the company to focus entirely on executing one of the richest structural heart pipelines in MedTech.
Where is the EW Stock Headed?
The strong Q4 beat and raised EPS confidence set Edwards Lifesciences stock up for a catalyst-heavy 2026, with next-gen PASCAL, U.S. tricuspid approval, SAPIEN M3 scaling, and a potential CMS TAVR coverage expansion all still ahead of investors.
EW stock’s fundamental case rests on Street estimates projecting 2026 revenue of $6.67 billion (+9.9% YoY) and normalized EPS of $2.95 (+15.4%), with EBIT margins expanding to 28.8% as the company leverages its structural heart focus into sustained double-digit earnings growth.
Wall Street turned notably more bullish in recent months, with Buy and Outperform ratings climbing to 21 combined against just 12 Holds as of February 19, and a mean price target of $96.50 sitting 22.3% above the current price of $78.92.
The target range for EW stock spans from a low of $84 to a high of $110, reflecting genuine debate about how quickly TMTT scales toward its $2 billion 2030 target and whether the CMS TAVR NCD expansion delivers meaningful volume in 2027 or later.
A mid-case DCF model prices Edwards at $134.45 by December 2030, implying a 70.4% total return and an 11.6% annualized IRR from current levels, making the stock look materially undervalued relative to the quality and durability of its structural heart franchise.
The primary risk is P/E multiple compression, with the model assuming a 2.9% annual P/E contraction, meaning Edwards must sustain nearly 12% EPS growth just to offset valuation de-rating, a challenging ask if TMTT adoption disappoints or the PROGRESS moderate AS trial data underwhelms at TCT.
At $78.92, Edwards trades well below both analyst consensus and the DCF fair value, making it look undervalued for investors who believe the structural heart market still has a decade of durable double-digit growth ahead of it.
X Stock Valuation Model Results (TIKR)
Value Any Stock in Under 60 Seconds (It’s Free)
With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
